-
Time to Innovate for Faster, Smarter Discovery and Clinical Development Cycles
Aug 6, 2020, 08:24 AM by User Not FoundBio-IT World Contributed Commentary | We’ve learned so much living through these unprecedented times. One lesson is the need to mobilize quickly, provide effective testing and contact tracing, and accelerate the development of therapies and vaccines to protect the global community. That can only be done through the power of data: the defining currency in drug discovery and clinical development.Full story -
Over 300 Clinical Studies Benefit from CluePoints COVID-19 Risk Management Support
Aug 6, 2020, 08:10 AM by Michael CroftKING OF PRUSSIA, PA - Aug 6, 2020 - CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced the success of its complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trialsFull story -
Raremark® launches the Xperiome™ patient-powered knowledge platform to deliver new therapies faster and smarter
Aug 6, 2020, 08:04 AM by Michael CroftLONDON, UK - Aug 6, 2020 - Raremark®, the leading online patient community in rare disease, has today launched its patient-powered knowledge platform Xperiome to help the pharmaceutical industry deliver innovative new therapies faster and smarterFull story -
Follow the Money: Cash for AI Models, Oncology, Hematology Therapies
Aug 5, 2020, 15:10 PM by Michael CroftBio-IT World Sema4 gets $121M to build dynamic models of human health and define optimal, individualized health trajectories. Glioblastoma, hematology, and acute pancreatitis all see new funding for therapy development. And AI-powered models net cash.Full story -
Ancestry Launches NGS Tests With Family History Component
Aug 4, 2020, 07:50 AM by Michael CroftFull storyBio-IT World | Ancestry has launched AncestryHealth powered by Next Generation Sequencing. It is an upgrade to AncestryDNA + Traits, adding genetic health risk reports, a family health history tool, and other resources.
-
Panthera’s UK oncology clinical trial sites open for studies
Aug 3, 2020, 14:16 PM by Michael CroftPRESTON, UNITED KINGDOM - Aug 3, 2020 -Full story- More than 1000 International Cancer Trials Suspended Due to COVID-19
- Panthera working with the state of the art Rutherford Cancer Centres across the UK is open for clinical research activities including screening
-
Sterling Signs Deal to Produce Potential COVID-19 Drug Candidate for Moleculin
Aug 3, 2020, 13:46 PM by Michael CroftCRAMLINGTON, UNITED KINGDOM - Jul 27, 2020 - Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has signed an agreement with Moleculin Biotech, IncFull story -
Abzena appoints Matthew LeClair as SVP and Site Head of San Diego Operations
Aug 3, 2020, 13:44 PM by Michael CroftSAN DIEGO, CA, UNITED KINGDOM - Aug 3, 2020 - Cambridge, UK and San Diego, CA, 3 August 2020 - Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Matthew LeClair as Senior Vice President (SVP) and Site Head of its San Diego OperationsFull story -
SkinCheck affordable skin cancer screening re-opens
Aug 3, 2020, 10:11 AM by Michael CroftCAMBRIDGE, UK - Aug 3, 2020 - Check4Cancer, the reliable and trusted provider of early cancer detection and genetic services in the UK, is reopening its SkinHealth SkinCheck clinics following enforced closure due to COVID-19Full story -
One Small Step For Open Science, One Giant Leap For Metastasis Research
Aug 3, 2020, 08:40 AM by Michael CroftFull storyBio-IT World | In a first-of-its-kind collaboration, researchers from 19 academically affiliated international laboratories have agreed to share their cell line models specific to brain metastasis with pretty much anyone who asks for them.
-
LUMICKS enters collaboration with Glycostem to enhance NK cell-mediated immunotherapy
Aug 3, 2020, 07:00 AM by Michael CroftAMSTERDAM, THE NETHERLANDS - Aug 3, 2020 - LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug developmentFull story -
Creative Peptides Provides Synthetic Peptides for Developing Vaccines
Aug 3, 2020, 05:05 AM by Michael CroftSHIRLEY, NY - Aug 3, 2020 - In the current COVID-19 pandemic, synthetic peptides play an important role in vaccine development. Creative Peptides, a supplier mainly engaged in the production of biologically active peptides, recently announced that it can provide synthetic peptides for vaccine developmentFull story -
Alfa Chemistry Materials—a New Option of Material Building Blocks
Aug 1, 2020, 01:55 AM by Michael CroftNY, NY - Aug 1, 2020 - Material building blocks are of vital importance in various areas such as in the production of semiconductorsFull story -
New Data on Genetic Expression In Severe COVID-19, Pre-Existing Immune Response
Jul 31, 2020, 08:35 AM by Michael CroftFull storyBio-IT World | Research continues to uncover the underlying biology of SARS-CoV-2 and reveal some surprises. A German team found that 35% of their healthy controls had pre-existing SARS-CoV-2 cross-reactive T cells, and several groups are narrowing down the gene expression signatures that might explain why COVID-19 is so severe in some patients.
-
Mitrefinch adds Facial Recognition to its Time and Attendance Solutions
Jul 30, 2020, 16:58 PM by Michael CroftNEWTON, MA - Jul 30, 2020 - Mitrefinch delivers biometric and cloud based time and attendance solutions for midsize and large organizations including hospitals, medical facilities and senior care centers across North and South AmericaFull story -
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies
Jul 30, 2020, 12:33 PM by Michael CroftHOPKINTON, MA, UNITED STATES - Jul 29, 2020 - Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (Spring Bank), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, and F-star Therapeutics, Limited (F-star), a privately-held clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2) antibodies, today announced that the companies have entered into a definitive share exchange agreement pursuant to which Spring Bank will, subject to stockholder approval, acquire all of the outstanding share capital of F-star in exchange for newly issued shares of Spring Bank in an all-stock transactionFull story -
Celsius Therapeutics, Twist Bioscience, And More: News From July 2020
Jul 30, 2020, 08:50 AM by Michael CroftFull storyBio-IT World July featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Celsius Therapeutics, Twist Bioscience, and more.
-
Agendia Expands Management Team to Meet Company Momentum, Appoints Brian Dow as Chief Financial Officer
Jul 29, 2020, 15:11 PM by Michael CroftIRVINE, CA - Jul 29, 2020 - Irvine, California, July 29, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the appointment of Brian Dow as Chief Financial Officer in the continued buildout of the Companys leadership teamFull story -
CareCom Joins Lyniate’s Co-Creation Lab to Address Interoperability
Jul 29, 2020, 09:08 AM by Michael CroftBOSTON, MA, UNITED STATES - Jul 29, 2020 - Lyniate, a global leader in healthcare data interoperability, today announced a partnership with CareCom, a leading provider of terminology services management, to drive interoperability innovationFull story -
Abzena Receives Growth Capital Investment from Newly Launched Biospring Partners
Jul 28, 2020, 08:56 AM by Michael CroftCAMBRIDGE, UNITED KINGDOM - Jul 28, 2020 - Cambridge, UK, Bristol, PA and San Diego, CA -28 July 2020 - Abzena, a leading global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firmFull story